secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2021-12-08T23:59:59+00:00
Accession:  0000950170-21-005077
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix appoints Dr. Jon Faiz Kayyem to board of directors effective December 6, 2021
--------------------------------------------------------------------------------

- Dr. Kayyem brings 20+ years experience in molecular diagnostics, having founded GenMark Diagnostics and Clinical Micro Sensors.
- Initial equity grant of $375,000: 50,368 NQSOs (5-year vest) and 31,619 RSUs (1-year vest).
- Prorated annual grant of $87,397: 27,038 NQSOs vesting March 31, 2022, strike at close on December 7, 2021.
- Appointed to Compensation Committee effective December 7, 2021; term expires at 2024 Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017021005077/0000950170-21-005077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017021005077/bdsx-20211206.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-005077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer